Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China.

ABSTRACT:

Objective

Camrelizumab is a selective, humanised, high-affinity IgG₄ kappa monoclonal antibody against programmed cell death 1 that shows effective antitumour activity with acceptable toxicity in multiple tumour types. The CameL trial demonstrated that camrelizumab plus chemotherapy (CC) significantly prolonged the median progression-free survival and median overall survival versus chemotherapy alone (CA) in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Our study was conducted to investigate the cost-effectiveness of the two strategies in chemotherapy-naive patients with advanced non-squamous NSCLC.

Design, setting and participants

A Markov simulation model was generated based on the CameL trial. The two simulated treatments included CC a

SUBMITTER: Xie Q 

PROVIDER: S-EPMC9362787 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature